Literature DB >> 21870215

Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity.

Yoshinobu Konno1, Yuki Kobayashi, Ken Takahashi, Eiji Takahashi, Shinji Sakae, Masako Wakitani, Kazuya Yamano, Toshiyuki Suzawa, Keiichi Yano, Toshio Ohta, Masamichi Koike, Kaori Wakamatsu, Shinji Hosoi.   

Abstract

Antibody-dependent cellular cytotoxicity (ADCC) is dependent on the fucose content of oligosaccharides bound to monoclonal antibodies (MAbs). As MAbs with a low fucose content exhibit high ADCC activity, it is important to control the defucosylation levels (deFuc%) of MAbs and to analyze the factors that affect deFuc%. In this study, we observed that the deFuc% was inversely related to culture medium osmolality for MAbs produced in the rat hybridoma cell line YB2/0, with r (2) values as high as 0.92. Moreover, deFuc% exhibited the same correlation irrespective of the type of compound used for regulating osmolality (NaCl, KCl, fucose, fructose, creatine, or mannitol) at a culture scale ranging from 1 to 400 L. We succeeded in controlling MAb deFuc% by maintaining a constant medium osmolality in both perfusion and fed-batch cultures. In agreement with these observations, reverse transcription PCR analyses revealed decreased transcription of genes involved in glycolysis, GDP-fucose supply, and fucose transfer under hypoosmotic conditions.

Entities:  

Year:  2011        PMID: 21870215      PMCID: PMC3386387          DOI: 10.1007/s10616-011-9377-2

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  71 in total

Review 1.  Economic aspects of commercial manufacture of biopharmaceuticals.

Authors:  Rolf G Werner
Journal:  J Biotechnol       Date:  2004-09-30       Impact factor: 3.307

2.  The culture of rat myeloma and rat hybridoma cells in a protein-free medium.

Authors:  M J Keen
Journal:  Cytotechnology       Date:  1995-10       Impact factor: 2.058

Review 3.  Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies.

Authors:  Wendy S Putnam; Saileta Prabhu; Yanan Zheng; Meena Subramanyam; Yow-Ming C Wang
Journal:  Trends Biotechnol       Date:  2010-08-04       Impact factor: 19.536

4.  Transcriptomic responses to sodium chloride-induced osmotic stress: a study of industrial fed-batch CHO cell cultures.

Authors:  Duan Shen; Thomas R Kiehl; Sarwat F Khattak; Zheng Jian Li; Aiqing He; Paul S Kayne; Vishal Patel; Isaac M Neuhaus; Susan T Sharfstein
Journal:  Biotechnol Prog       Date:  2010 Jul-Aug

Review 5.  Production of recombinant protein therapeutics in cultivated mammalian cells.

Authors:  Florian M Wurm
Journal:  Nat Biotechnol       Date:  2004-11       Impact factor: 54.908

6.  Biopharmaceutical benchmarks 2006.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2006-07       Impact factor: 54.908

Review 7.  Optimal and consistent protein glycosylation in mammalian cell culture.

Authors:  Patrick Hossler; Sarwat F Khattak; Zheng Jian Li
Journal:  Glycobiology       Date:  2009-06-03       Impact factor: 4.313

8.  Estimation of dissolved carbon dioxide stripping in a large bioreactor using model medium.

Authors:  Naoki Matsunaga; Kenjiro Kano; Yasuyuki Maki; Toshiaki Dobashi
Journal:  J Biosci Bioeng       Date:  2009-04       Impact factor: 2.894

9.  Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC.

Authors:  Yutaka Kanda; Naoko Yamane-Ohnuki; Naoto Sakai; Kazuya Yamano; Ryosuke Nakano; Miho Inoue; Hirofumi Misaka; Shigeru Iida; Masako Wakitani; Yoshinobu Konno; Keiichi Yano; Kenya Shitara; Shinji Hosoi; Mitsuo Satoh
Journal:  Biotechnol Bioeng       Date:  2006-07-05       Impact factor: 4.530

10.  A new vector for the high level expression of chimeric antibodies in myeloma cells.

Authors:  K Shitara; K Nakamura; Y Tokutake-Tanaka; M Fukushima; N Hanai
Journal:  J Immunol Methods       Date:  1994-01-03       Impact factor: 2.303

View more
  9 in total

Review 1.  Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.

Authors:  Vyanka Redenbaugh; Eoin P Flanagan
Journal:  Neurotherapeutics       Date:  2022-03-10       Impact factor: 6.088

Review 2.  Immune Correlate-Guided HIV Vaccine Design.

Authors:  Galit Alter; Dan Barouch
Journal:  Cell Host Microbe       Date:  2018-07-11       Impact factor: 21.023

3.  Comprehensive manipulation of glycosylation profiles across development scales.

Authors:  Sven Loebrich; Elisa Clark; Kristina Ladd; Stefani Takahashi; Anna Brousseau; Seth Kitchener; Robert Herbst; Thomas Ryll
Journal:  MAbs       Date:  2018-10-22       Impact factor: 5.857

Review 4.  Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: From Bench to Bedside.

Authors:  Wenli Zhu; Yaling Zhang; Zhen Wang; Ying Fu; Yaping Yan
Journal:  Neurosci Bull       Date:  2020-06-12       Impact factor: 5.203

5.  A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.

Authors:  Ahmed Sawas; Charles M Farber; Marshall T Schreeder; Mazen Y Khalil; Daruka Mahadevan; Changchun Deng; Jennifer E Amengual; Petros G Nikolinakos; Jill M Kolesar; John G Kuhn; Peter Sportelli; Hari P Miskin; Owen A O'Connor
Journal:  Br J Haematol       Date:  2017-02-21       Impact factor: 6.998

Review 6.  Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components

Authors:  Fatemeh Torkashvand; Behrouz Vaziri
Journal:  Iran Biomed J       Date:  2017-04-20

7.  Characterization of Monoclonal Antibody Glycan Heterogeneity Using Hydrophilic Interaction Liquid Chromatography-Mass Spectrometry.

Authors:  Sumit K Singh; Kelvin H Lee
Journal:  Front Bioeng Biotechnol       Date:  2022-01-11

8.  Osmolality Effects on CHO Cell Growth, Cell Volume, Antibody Productivity and Glycosylation.

Authors:  Sakhr Alhuthali; Pavlos Kotidis; Cleo Kontoravdi
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

Review 9.  A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.

Authors:  Esther S Frisch; Roxanne Pretzsch; Martin S Weber
Journal:  Neurotherapeutics       Date:  2021-04-20       Impact factor: 7.620

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.